Press Releases

News from the year: /2013

Oxford Biomedica Appoints Catherine Moukheibir as Non-Executive Director

Oxford, UK – 14 December 2021: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, announces the appointment of Ms Catherine Moukheibir to the Board as an Independent Non-Executive Director with effect from today. Ms Moukheibir has extensive international experience in finance, capital… Read More

Read more

Oxford Biomedica Signs Licence & Supply Agreement with Arcellx, Inc. for LentiVector® Platform for CAR-T Therapeutics

Oxford, UK – 13 December 2021: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that it has signed a new Licence and Supply Agreement (“LSA”) with Arcellx, Inc. (“Arcellx”), a Gaithersburg MD.-based biotechnology company developing novel, adaptive and controllable… Read More

Read more

Boehringer Ingelheim Exercises Option

Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK – 19 October 2021: Oxford Biomedica plc (LSE:Oxford Biomedica) (“Oxford Biomedica” or “the Group”), a leading gene and cell therapy group, today announces that Boehringer Ingelheim has exercised its option… Read More

Read more

Interim results for the six months ended 30 June 2021

Oxford Biomedica delivers record first half results Oxford, UK – 22 September 2021: Oxford Biomedica plc (“Oxford Biomedica” or “the Group”) (LSE: Oxford Biomedica), a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2021. John Dawson, Oxford Biomedica’s Chief Executive Officer,… Read More

Read more

Notice of Interim Results

London, UK – 1 September 2021: Oxford Biomedica plc (LSE:Oxford Biomedica), a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2021 on Wednesday 22 September 2021. A briefing for analysts will be held at 13:00 BST / 08:00 EST… Read More

Read more